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Abstract 
Background: To elucidate the optimal number of prostate biopsy cores using a nomogram allocating 6–12 biopsy 
cores, the number generally used in daily practice, based on age and prostate volume (PV).
Methods: We enrolled 936 patients who received an initial prostate biopsy from April 2006 to January 2009. A num‑
ber of 6–12 biopsy cores was allocated based on age and PV Nara Urological Research and Treatment Group (NURTG) 
nomogram. To elucidate the predictive parameters of cancer detection in patients with a prostate specific antigen 
(PSA) value in the gray zone, univariate and multivariate logistic regression analysis were carried out.
Results: The total cancer detection rate and the cancer detection rate in the PSA gray zone (4.1–10.0 ng/mL) were 
48.0 and 37.6 %, respectively. The cancer detection rates in the gray zone stratified by patient age of ≤59, 60–64, 
65–69, 70–74, 75–79, and ≥80 years were 28.4, 35.0, 26.9, 37.9, 45.7, and 54.8 %, respectively. The significant predic‑
tive parameters of cancer detection in the gray zone were age, volume biopsy ratio (VBR: PV divided by number of 
biopsy cores), PSA density (PSAD), digital rectal examination findings, and transrectal ultrasound findings in univariate 
analyses. Finally, age, VBR, and PSAD were independent parameters to predict cancer detection in the gray zone. The 
adverse event profile was acceptable.
Conclusions: Our present study revealed that the cancer detection rate using the NURTG nomogram allocating 
6–12 biopsy cores, the number generally used in daily practice, based on age and PV, could provide similar efficacy as 
previous studies involving more biopsy cores. In older patients the number of biopsy cores could be reduced.
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Background
Since the concept of systematic prostate biopsy has been 
introduced, the number of biopsy cores has increased to 
12 cores. At first, sextant systematic biopsy was proposed 
[1]. The number of cores gradually increased to improve 
the cancer detection rate. Remzi et  al. introduced the 
Vienna nomogram, allocating a number of 6–18 (mean 
10) cores based on the patients’ age and prostate volume 
(PV). They concluded that the cancer detection rate was 
36.7 % in the gray zone of prostate specific antigen (PSA) 
(4.0–10.0  ng/mL) [2]. The concept of Remzi’s report 
to decide the number of cores based on age and PV is 
appropriate, because the meaning of the same number of 
cores for prostates of different volume is unscientific. The 
volume guaranteed by a biopsy core varied. For exam-
ple, if 12 core biopsies were performed in patients with a 
60 mL prostate, one core would cover 5 mL, but in case of 
a 12 mL prostate one core would cover 1 mL. We believe 
that the number of cores should be determined based on 
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PV. To increase the number of cores increases the cancer 
detection rate. On the other hand, the optimal number of 
cores is an open question.
To shed light on these issues, we conducted this pro-
spective study to evaluate the NURTG (Nara Urological 
Research and Treatment Group: former Nara Urological 
Oncology Research Group: NUORG) nomogram allocat-
ing 6–12 biopsy cores, the number generally used in daily 
practice, based on age and PV.
Methods
This prospective study was conducted at Nara Medical 
University and its three affiliate hospitals (Yamatotakada 
City Hospital, Hirao Hospital, and Saiseikai Chuwa Hos-
pital). We enrolled 936 patients who received an initial 
prostate biopsy from April 2006 to January 2009. The 
criteria for the indication of biopsy were abnormal PSA 
value, abnormal findings of digital rectal examination 
(DRE) and abnormal findings by transrectal ultrasound. 
Patients were excluded from this study if they had an 
acute or chronic prostatitis, urinary retention, urinary 
tract infection or indwelling urinary catheter.
We adopted the age-specific reference range of PSA for 
the cut-off value of PSA [3]. The PSA cut-off value were 
3.1 ng/mL for patients less than 65 years, 3.6 ng/mL for 
65–69 years, and 4.1 ng/mL for 70 years or older, respec-
tively. The number of biopsy cores allocated was from 6 
to 12 cores based on age and PV (NURTG nomogram) 
(Table  1). This nomogram was designed based on the 
previous reports by Remzi [2] and Ito [4]. The maximum 
number of biopsy cores were 18 [2] and 20 [4] in the pre-
vious studies. In the present study, we set the maximum 
number of biopsy cores as 12 cores because 12 cores is an 
appropriate number in daily practice. The principal por-
tion of the biopsy was that of sextant systematic biopsy. 
Additional cores were located to the far lateral region 
(Fig. 1). Prostate needle biopsy was performed using an 
automatic biopsy gun with an 18-gauge needle under 
transrectal ultrasound (TRUS) guidance. PV was calcu-
lated using the formula for prostate ellipsoid (transverse 
width × transverse length × longitudinal height × 0.52). 
Two pathologists (K.N. and S.K.), both experts in prostate 
cancer diagnosis, centrally reviewed the Gleason score of 
all biopsy specimens.
We evaluated the cancer detection rate of the NURTG 
nomogram in all patients as well as patients with a PSA 
value in the gray zone (4.1–10.0  ng/mL). The statistical 
difference between the cancer group and the non-cancer 
group for categorical variables was tested by the Chi-
square test, while that for continuous variables was tested 
by the t-test. We evaluated adverse events of grade 2 or 
greater related prostate biopsy using common terminol-
ogy criteria adverse events version 4.0. To elucidate the 
predictive parameters of cancer detection in patients with 
a PSA value in the gray zone, univariate and multivariate 
logistic regression analysis were carried out using clini-
cal parameters such as age, volume biopsy ratio (VBR: PV 
divided by number of cores), PSA density (PSAD: PSA 
value divided by PV) [5], DRE findings, and TRUS find-
ings. Variables that were found to be significant in the 
univariate analyses (p < 0.05) were entered into the mul-
tivariate analysis. All statistical analyses were performed 
using PASW statistics 17.0 (SPSS Inc., Chicago, IL, USA). 
All p values of less than 0.05 were considered statistically 
significant.
The institutional reviewer board (Nara Medical Univer-
sity) approved this prospective study, and informed con-
sent by the patients was exempted in view of the aim and 
methods of this study.
Results
The patient characteristics are shown in Table  2. The 
median age and PSA value were 70 years and 5.8 ng/mL, 
respectively, in the no cancer group, and 73  years and 
10.1 ng/mL, respectively in the cancer group. The median 
age and PSA value of the cancer group were significantly 
higher than those in the no cancer group (p < 0.001, and 
p = 0.008). The median PV and PSAD were 38.8 mL and 
Table 1 The number of  biopsy cores stratified by  age 
and prostate volume (NURTG nomogram)
Prostate volume (mL) Age
≤59 60–64 65–69 70≤
−25 12 10 8 6
25–50 12 12 10 8
50− 12 12 12 10
Standard sextant biopsy
Additional biopsy site
Fig. 1 The principal portion and additional portion of biopsy cores. 
Red circle indicates additional site and blue circle indicates standard 
sextant systematic biopsy
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0.15 ng/mL/mL, respectively, in the no cancer group, and 
28.1 mL and 0.41 ng/mL/mL, respectively, in the cancer 
group. The median PV in the no cancer group was sig-
nificantly larger than that in the cancer group (p < 0.001), 
while the median PSAD in the no cancer group was 
significantly smaller than that in the cancer group 
(p = 0.005). The median VBR of the no cancer group was 
4.22, while that in the cancer group was 3.64. The median 
VBR of the no cancer group was significantly larger than 
that in the cancer group (p < 0.001). The distribution of 
a Gleason score of ≤6, 7, and 8–10 were 32.0, 47.2 and 
20.8 %, respectively.
Cancer detection rate stratified by PSA distribution, patient 
age and PV
The cancer detection rate stratified by PSA distribution is 
shown in Table 3. The cancer detection rate stratified by 
PSA value from, 0–4, 4–10, 10–20, 20–30, 30–40, 40–50, 
50–10, and more than 100  ng/mL was 20.7, 37.6, 58.4, 
80.6, 87.5, 100, 93.3, and 100  %, respectively. The can-
cer detection rate gradually increased according to the 
increase in the PSA value.
The cancer detection rate stratified by patient age 
and PV in all patients is shown in Table  4. The cancer 
detection rate stratified by patient age of  ≤59, 60–64, 
65–69, 70–74, 75–79, and ≥80 was 25.8, 39.8, 39.8, 46.4, 
59.8, and 68.0 %, respectively. The cancer detection rate 
in older patients was higher than that in younger patients 
(p  <  0.001). The cancer detection rate stratified by PV 
of ≤25, 25.1–50, and ≥50.1 were 29.9, 43.8, and 66.1 %, 
respectively. Older patients and those with a small PV 
showed higher cancer detection rates (p < 0.001). These 
trends also could be seen in for the gray zone PSA lev-
els (4.1–10.0  ng/mL) (p  <  0.001) (Table  5). The cancer 
detection rate in the gray zone was 37.6  %. The cancer 
detection rate in the gray zone stratified by patient age 
of ≤59, 60–64, 65–69, 70–74, 75–79, and ≥80 years were 
28.4, 35.0, 26.9, 37.9, 45.7, and 54.8 %, respectively. The 
cancer detection rate in the gray zone stratified by PV 
of ≤25, 25.1–50, and ≥50.1 was 20.4, 31.3, and 58.1  %, 
respectively.
The total number of biopsy cores was 8420 in this 
study. Approximately, 25  % of biopsy cores could be 
reduced using the NURTG nomogram compared with 
12-cores biopsy (8420 cores vs. 11,232 cores).
The significant predictive parameters of cancer detec-
tion in the gray zone were age, VBR, PSAD, DRE find-
ings, and TRUS findings in univariate analyses. Finally, 
Table 2 Patients’ background
All patients (n = 936) No cancer (n = 487) Cancer (n = 449) p value
Age <0.001
 Mean (median) 71 (71) 69 (70) 73 (73)
 Range 22–94 22–89 49–94
PSA (ng/mL) 0.008
 Mean (median) 58.5 (7.1) 7.4 (5.8) 114.0 (10.1)
 Range 0.3–16,920 0.3–83.6 0.6–16,920
PV (mL) <0.001
 Mean (median) 38.0 (33.2) 43.6 (38.8) 32.0 (28.1)
 Range 6–176 6–176 10–155
PSAD (ng/mL/mL) 0.005
 Mean (median) 1.99 (0.22) 0.21 (0.15) 3.94 (0.41)
 Range 0.0–480.7 0.0–3.1 0.0–480.7
VBR (volume biopsy ratio) (mL/core) <0.001
 Mean (median) 4.17 (3.89) 4.50 (4.22) 3.80 (3.64)
 Range 0.46–17.62 0.46–17.62 0.86–15.47
Number of biopsy cores <0.001
 6 169 41 (24.3) 128 (75.7)
 8 331 161 (48.6) 170 (51.4)
 10 237 130 (54.9) 107 (45.1)
 12 199 155 (77.9) 44 (22.1)
Gleason score, no (%)
 ≦6 143 143 (32.0)
 7 211 211 (47.2)
 8–10 93 93 (20.8)
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age, VBR, and PSAD were independent parameters that 
predicted cancer detection in the gray zone (Table 6).
The profile of adverse events of grade 2 or greater 
related with prostate biopsy are shown in Table  7. One 
patient (0.1 %) suffered from grade 3 prostate infection. 
10 patients (0.5 %) showed acute grade 2 urinary reten-
tion. We experienced five patients (0.5 %) with hematuria 
(grade 2), five patients (0.5  %) with fever (grade 2), and 
two patients with rectal hemorrhage (0.2 %).
Discussion
In our previous retrospective studies on prostate biopsy 
[6, 7], we used 6–8 biopsy cores, and the cancer detection 
rate in all patients and patients with gray zone PSA was 
relatively low. Therefore, we conducted the present pro-
spective study to elucidate the usefulness of the NURTG 
nomogram allocating 6–12 biopsy cores, the number 
generally used in daily practice, based on age and PV. 
Consequently, the cancer detection rate in all patients 
and the cancer detection rate in gray zone PSA patients 
increased to 48.0 and 37.6 %, respectively.
Since Hodge introduced systematic sextant biopsy [1], 
the number of biopsy cores has increased to achieve a 
higher cancer detection rate [8–11]. For the initial diag-
nosis, a core biopsy of 10–12 systematic transrectal or 
transperineal peripheral zone biopsies under ultrasound 
imaging guidance is recommended by the guideline of 
the European Association of Urology [12]. Increasing the 
number of cores can expectedly lead to a higher cancer 
detection rate. For example, Kawakami et al. introduced 
a 3-D biopsy method with 26 cores. The cancer detec-
tion rate in the gray zone was 36.0 % [13]. Remizi et al. 
Table 3 Cancer detection rates according to PSA stratifica-
tion
PSA (ng/mL) Number of biopsies Cancer
n = 936 % n = 449 %
0–4 87 9.3 18 20.7
4–10 548 58.5 206 37.6
10–20 154 16.5 90 58.4
20–30 36 3.8 26 80.6
30–40 24 2.6 21 87.5
40–50 10 1.1 10 100.0
50–100 30 3.2 28 93.3
100< 47 5.0 47 100.0
Table 4 Cancer detection rates stratified by age and prostate volume in all patients
PV (mL) Age
−59 60–64 65–69 70–74 75–79 80− Total
−25 32.4 (11/34) 75.8 (25/33) 52.5 (31/59) 66.7 (42/63) 79.7 (47/59) 83.0 (39/47) 66.1 (195/295)
25.1–50 19.6 (9/46) 25.6 (11/43) 43.0 (37/86) 45.4 (59/130) 55.1 (49/89) 58.5 (31/53) 43.8 (196/447)
50.1− 30.8 (4/13) 13.6 (3/22) 14.6 (6/41) 21.7 (10/46) 42.6 (20/47) 60.0 (15/25) 29.9 (58/194)
Total 25.8 (24/93) 39.8 (39/98) 39.8 (74/186) 46.4 (111/239) 59.5 (116/195) 68.0 (85/125) 48.0 (449/936)
Table 5 Cancer detection rate stratified by age and prostate volume in gray zone patients
PV (mL) Age
−59 60–64 65–69 70–74 75–79 80− Total
−25 41.7 (10/24) 71.4 (15/21) 38.2 (13/34) 63.6 (28/44) 66.7 (20/30) 73.7 (14/19) 58.1 (100/172)
25.1–50 20.0 (7/35) 18.5 (5/27) 27.9 (12/43) 32.2 (28/87) 38.6 (17/44) 46.9 (15/32) 31.3 (84/268)
50.1− 25.0 (2/8) 8.3 (1/12) 11.1 (3/27) 16.7 (5/30) 30.0 (6/20) 45.5 (5/11) 20.4 (22/108)
Total 28.4 (19/67) 35.0 (21/60) 26.9 (28/104) 37.9 (61/161) 45.7 (43/94) 54.8 (34/62) 37.6 (206/548)
Table 6 Logistic regression analysis predicting positive 
biopsy in the gray zone
C.I. confidence interval
Variables                       Univariate Multivariate
p value Odds ratio p value Odds ratio 95 % CI
Age 0.005 1.038 0.001 1.053 1.022–1.084
VBR (median 
3.83)
<0.001 0.375 0.008 0.468 0.267–0.818
PSAD (median 
0.17)
<0.001 3.924 0.001 2.556 1.506–4.338
DRE 0.003 2.295 0.468 1.280 0.657–2.495
TRUS 0.002 2.232 0.081 1.690 0.937–3.048
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reported the Vienna nomogram in which a number of 
6–18 biopsy cores based on PV and age was set. The 
cancer detection rate was 36.7 % at a PSA level between 
2–10 ng/mL [2]. Is it indeed necessary to obtain such a 
large number of cores for the initial biopsy?
We conducted the present study to address the issue of 
the optimal number of cores in daily practice. We regu-
lated the number of cores from 6 to 12 based on patient age 
and PV. Younger patients and a larger PV were allocated to 
more biopsy cores. This concept was similar to that of the 
Vienna nomogram [2]. The cancer detection rate in the gray 
zone of the present study was 37.6 % (cf. Vienna nomogram 
36.7  %). Our present results revealed that the NURTG 
nomogram, which regulated the number of cores at 6–12 
based on age and PV, achieved similar cancer detec-
tion rates as previous studies conducted in larger cohorts 
(Table 8) [2, 13–15]. If all patients received 12-cores biopsy 
in this study cohort, the total number of biopsy cores was 
11,232. In fact, the total number of biopsy cores was 8420. 
Approximately, 2812 cores (25 %) could be reduced using 
the NURTG nomogram, and a huge decrease in pathology 
time and costs could be obtained. A small prostate is also 
an important and noteworthy sign of prostate cancer detec-
tion. Eventually, multivariate analysis showed that PSAD, 
VBR and age were independent parameters that predict 
prostate cancer in the gray zone (Table 6). Jiang et al. first 
reported that the cut-off value of VBR ≤4 was optimal for 
detecting cancer and avoiding excessive biopsy specimens 
in patients with PSA values of <20 ng/mL [5]. Miyoshi et al. 
also confirmed that VBR was an independent parameter 
to predict prostate cancer in patients with PSA values of 
4–20 ng/mL [16]. Our present results also confirmed that 
VBR (cut-off value 3.83) was an independent predictor of 
prostate cancer for gray zone PSA levels (4.1–10.0 ng/mL). 
We should interpret the meaning of VBR carefully. The fact 
that the cancer detection rate is higher in patients with a 
smaller VBR means that the number of biopsy cores is ade-
quate and that patients with a smaller PV are more likely 
to have prostate cancer. This result is also confirmed by the 
fact that patients with a higher PSAD show a higher can-
cer detection rate. In the present study, PSAD was also an 
independent predictor of prostate cancer detection like age 
and VBR (Table 6). Younger patients with a smaller PV also 
showed a lower cancer detection rate compared with older 
patients, independent of whether younger patients under-
went biopsy with a greater number of cores (Tables 4, 5). 
The conceivable reason for these results is that the cancer 
volume of younger patients is probably smaller than that of 
older patients.
The present study showed an acceptable result of 
adverse events after biopsy (Table  7). The incidence of 
adverse events ≥grade 2 after prostate biopsy was accept-
able compared with previous studies [17]. We believe 
that our method using NURTG nomogram is safe and 
reliable in respect of adverse events. The cancer detec-
tion rate in our study is also equivalent to that in previous 
studies with a greater number of biopsy cores (Table 8). 
The number of biopsy cores can be reduced in patients 
of ≥70 years of age instead of the uniform 12-core biopsy.
Conclusion
Our present study revealed that the cancer detection 
rate using the NURTG nomogram allocating a number 
Table 7 Incidence rate of  adverse event ≥ grade 2 after 
prostate biopsy (CTCAE ver. 4.0)
Grade 2 Grade 3
Hematuria 0.5 (5)
Rectal hemorrhage 0.2 (2)
Prostate infection 0.5 (5) 0.1 (1)
Acute urinary retention 1.1 (10)
Fever 0.5 (5)
Table 8 Comparison of cancer detection rates in previous reports of studies in large numbers of patients
TZ transition zone, TP transperineal biopsy, TR transrectal biopsy, NA not available
Reference No of pts No of cores TZ biopsy PSA range Cancer detection rate (%)
All cases Gray zone
Ung [14] 750 12 (6–18) NA 0.3–67.0
Median 4.4
33.7 NA
Remzi [2] 502 
Vienna nomogram
6–18 (mean 10) NA 2–10 36.7
Kawakami [13] 663 26 (TP16 + TR12) + <20 36 36
(4–939)
Takenaka [15] 247 
repeat 58
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of 6–12 biopsy cores, the number generally used in daily 
practice, based on age and PV could lead to similar 
efficacy compared with previous studies with a more 
expanded number of biopsy cores. In older patients the 
number of biopsy cores can be reduced.
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